secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020313
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M
--------------------------------------------------------------------------------

- 4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.
- FY24 total revenue $179.3M; net product sales $144.9M (+39% YoY); net income $17.5M vs loss $25.1M in FY23.
- Cash & short-term investments $77.3M at year-end, up from $56.9M; expects positive net income in FY25.
- FY25 guidance: total revenue $200-210M; net product sales $185-192M; contract revenues $15-18M.
- R289 granted Fast Track and Orphan Drug designations for MDS; partner TAVALISSE approvals in South Korea and Mexico.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/0001104659-25-020313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/tm258144d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer